FibroBiologics (FBLG) vs Immuron (IMRN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immuron is the larger company by market cap ($9.0 million vs $7.7 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBLG | IMRN |
|---|---|---|
| Share price | $1.11 | $1.11 |
| Market cap | $7.72M | $8.96M |
| 1-day change | -2.63% | +1.83% |
| EPS (TTM) | $-5.01 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.28 | $2.39 |
| 52-week low | $0.62 | $0.677 |
| Distance from 52-week high | -89.20% | -53.56% |
| Analyst consensus | none | none |
| Avg. price target upside | +1026.13% | +250.45% |
| Average volume | 204.43K | 2.06M |
| Shares outstanding | 6.96M | 8.07M |
| Employees | 15 | 7 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About FibroBiologics
FBLG stock →FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis.
Healthcare · Biotechnology · 15 employees
About Immuron
IMRN stock →Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products.
Healthcare · Biotechnology · 7 employees
FBLG vs IMRN FAQ
Which is bigger, FibroBiologics or Immuron?
Immuron (IMRN) is larger, with a market capitalization of $8.96M compared with $7.72M for FibroBiologics (FBLG).
Are FibroBiologics and Immuron in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.